Published in Pharmacogenomics J on October 05, 2010
Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study. Diabetes (2014) 1.29
Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs). Toxicol Appl Pharmacol (2013) 0.91
Hepatocyte nuclear factor 1 regulates the expression of the organic cation transporter 1 via binding to an evolutionary conserved region in intron 1 of the OCT1 gene. J Pharmacol Exp Ther (2013) 0.91
PharmGKB summary: tramadol pathway. Pharmacogenet Genomics (2014) 0.89
Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology. Biomed Res Int (2013) 0.87
OCT1 genetic variants influence the pharmacokinetics of morphine in children. Pharmacogenomics (2013) 0.87
Ontogeny of Hepatic Drug Transporters as Quantified by LC-MS/MS Proteomics. Clin Pharmacol Ther (2016) 0.86
Membrane transporters as mediators of Cisplatin effects and side effects. Scientifica (Cairo) (2012) 0.81
Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics. Clin Pharmacokinet (2016) 0.81
Stability of butorphanol-tropisetron mixtures in 0.9% sodium chloride injection for patient-controlled analgesia use. Medicine (Baltimore) (2015) 0.81
Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists? Curr Oncol Rep (2013) 0.80
Genetic factors associated with pharmacotherapy and background sensitivity to postoperative and chemotherapy-induced nausea and vomiting. Exp Brain Res (2014) 0.80
Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions. Pharmacogenomics J (2015) 0.80
Tramadol Extended-Release for the Management of Pain due to Osteoarthritis. ISRN Pain (2013) 0.77
The poorly membrane permeable antipsychotic drugs amisulpride and sulpiride are substrates of the organic cation transporters from the SLC22 family. AAPS J (2014) 0.77
Quinine enhances the behavioral stimulant effect of cocaine in mice. Pharmacol Biochem Behav (2014) 0.77
Effect of Ondansetron on Metformin Pharmacokinetics and Response in Healthy Subjects. Drug Metab Dispos (2016) 0.75
PharmGKB summary: very important pharmacogene information for SLC22A1. Pharmacogenet Genomics (2014) 0.75
Global genetic analyses reveal strong inter-ethnic variability in the loss of activity of the organic cation transporter OCT1. Genome Med (2015) 0.75
DNA diagnostics--molecular techniques and automation. Science (1988) 8.85
A ligase-mediated gene detection technique. Science (1988) 7.61
Public-health impact of outdoor and traffic-related air pollution: a European assessment. Lancet (2000) 6.95
Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A (2000) 5.89
Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet (1997) 3.08
Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry (2004) 2.98
Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation (1998) 2.90
Automated DNA diagnostics using an ELISA-based oligonucleotide ligation assay. Proc Natl Acad Sci U S A (1990) 2.88
Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol (1999) 2.57
European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis (2011) 2.47
Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect (2011) 2.23
The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics (2001) 2.21
The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther (2009) 2.19
Assessment of deaths attributable to air pollution: should we use risk estimates based on time series or on cohort studies? Am J Epidemiol (2001) 2.19
Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication. Antimicrob Agents Chemother (1995) 2.04
Development and clinical significance of the musculus dorsoepitrochlearis in men. Clin Anat (2009) 1.98
Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther (1999) 1.96
Nomenclature for human CYP2D6 alleles. Pharmacogenetics (1996) 1.91
T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus--positive blood donors without viremia. Hepatology (1996) 1.88
Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet (1995) 1.79
Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol (1999) 1.76
Epidemic intelligence: a new framework for strengthening disease surveillance in Europe. Euro Surveill (2006) 1.75
A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res (1996) 1.74
Increased frequency of the HLA-DR15 (B1*15011) allele in German patients with self-limited hepatitis C virus infection. Eur J Clin Invest (1999) 1.68
Mitochondrial aldehyde dehydrogenase from human liver. Primary structure, differences in relation to the cytosolic enzyme, and functional correlations. Eur J Biochem (1985) 1.65
CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand (2001) 1.59
Identification of clusters of biallelic polymorphic sequence-tagged sites (pSTSs) that generate highly informative and automatable markers for genetic linkage mapping. Genomics (1992) 1.55
Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J (2006) 1.53
Characterization of the glutathione S-transferase GSTT1 deletion: discrimination of all genotypes by polymerase chain reaction indicates a trimodular genotype-phenotype correlation. Pharmacogenetics (2000) 1.52
Collaboration, cholera, and cyclones: a project to improve point-of-use water quality in Madagascar. Am J Public Health (2001) 1.52
Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int (1999) 1.51
Release of chemosterilized males for the control of Anopheles albimanus in El Salvador. 3. Field methods and population control. Am J Trop Med Hyg (1974) 1.48
Parvovirus B19 DNA is frequently present in recombinant coagulation factor VIII products. Thromb Haemost (1996) 1.46
Roles of DnaK and RpoS in starvation-induced thermotolerance of Escherichia coli. J Bacteriol (1998) 1.42
Serological and virological markers of human parvovirus B19 infection in sera of hemophiliacs. Thromb Haemost (1994) 1.40
Immunosuppressive properties of cyclosporin metabolites. Lancet (1989) 1.39
[Influencing of mitosis rate in endometrial carcinomas using 17-hydroxynorprogesterone capronate in women]. Arch Gynakol (1972) 1.38
Prediction of response to antiretroviral therapy by human experts and by the EuResist data-driven expert system (the EVE study). HIV Med (2010) 1.24
Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. Clin Pharmacol Ther (1999) 1.23
Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther (1992) 1.22
Identification of the phosphorylation site for cAMP-dependent protein kinase on Na+,K(+)-ATPase and effects of site-directed mutagenesis. J Biol Chem (1994) 1.21
Decreased frequency of HCV core-specific peripheral blood mononuclear cells with type 1 cytokine secretion in chronic hepatitis C. J Hepatol (1999) 1.20
Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19. Pharmacogenomics J (2005) 1.19
Comparison of three classes of human liver alcohol dehydrogenase. Emphasis on different substrate binding pockets. Eur J Biochem (1990) 1.19
CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther (2006) 1.16
A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol (2011) 1.15
Purification, characterization and HPLC assay of Salmonella glucose-1-phosphate thymidylyl-transferase from the cloned rfbA gene. Eur J Biochem (1993) 1.14
Measurement of free and bound malondialdehyde in plasma by high-performance liquid chromatography as the 2,4-dinitrophenylhydrazine derivative. J Chromatogr B Biomed Sci Appl (2000) 1.13
Ligand requirements of the human corticotropin-releasing factor-binding protein. Endocrinology (1995) 1.11
Genotypic coreceptor analysis. Eur J Med Res (2007) 1.10
Blood donors in Kenya: a comparison of voluntary and family replacement donors based on a population-based survey. Vox Sang (2010) 1.10
Arylamine N-acetyltransferase activity in man. Drug Metab Rev (1999) 1.09
The role of health care in the spread of HIV/AIDS in Africa: evidence from Kenya. Int J STD AIDS (2009) 1.08
CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. J Immunol (1997) 1.08
[The value of pharmacogenetic tests in antidepressive medication therapy]. Nervenarzt (2005) 1.07
HLA-DQ6 and ingestion of contaminated water: possible gene-environment interaction in an outbreak of Leptospirosis. Genes Immun (2004) 1.07
Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice. Eur J Med Res (2010) 1.06
The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenomics J (2001) 1.05
Preliminary results on the action of cosmic heavy ions on the development of eggs of Artemia salina. Life Sci Space Res (1974) 1.05
Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10. Cancer Res (2001) 1.05
Heat-related mortality in selected United States cities, summer 1999. Am J Forensic Med Pathol (2001) 1.04
Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. Eur J Clin Pharmacol (1993) 1.04
Hazardous pharmacokinetic interaction of Saint John's wort (Hypericum perforatum) with the immunosuppressant cyclosporin. Int J Clin Pharmacol Ther (2000) 1.04
Comparison between a nucleic acid sequence-based amplification and branched DNA test for quantifying HIV RNA load in blood plasma. J Virol Methods (2000) 1.03
Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant--463A of the myeloperoxidase gene. Cancer Res (2000) 1.03
Sodium selenite and N-acetylcysteine in antiretroviral-naive HIV-1-infected patients: a randomized, controlled pilot study. Eur J Clin Invest (1998) 1.02
Catalytic mechanism of serine proteases: reexamination of the pH dependence of the histidyl 1J13C2-H coupling constant in the catalytic triad of alpha-lytic protease. Proc Natl Acad Sci U S A (1981) 1.01
Release of chemosterilized males for the control of Anopheles albimanus in El Salvador. IV. Dynamics of the test population. Am J Trop Med Hyg (1974) 1.01
Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1). Biochem Pharmacol (1999) 1.00
Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours. Curr Oncol (2012) 1.00
Impact of the safe water system on water quality in cyclone-affected communities in Madagascar. Am J Public Health (2001) 1.00
Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. Br J Clin Pharmacol (2002) 1.00
Persistence of haloperidol in human brain tissue. Am J Psychiatry (1999) 0.98
The failure to separate human X-and Y-spermatozoa by the millipore filtration technique. J Reprod Med (1978) 0.98
Rapid detection and quantitation of precipitating streptokinase-antibodies. Thromb Diath Haemorrh (1974) 0.97
High benzo[a]pyrene diol-epoxide DNA adduct levels in lung and blood cells from individuals with combined CYP1A1 MspI/Msp-GSTM1*0/*0 genotypes. Pharmacogenetics (1998) 0.97
[Indications for appendectomy from the ultrasound-clinical viewpoint]. Zentralbl Chir (1998) 0.97
L -dopa-induced adverse effects in PD and dopamine transporter gene polymorphism. Neurology (2003) 0.96
Cyclosporin metabolites and central-nervous-system toxicity. Lancet (1988) 0.96
Polymorphisms in the human CYP1A1 gene as susceptibility factors for lung cancer: exon-7 mutation (4889 A to G), and a T to C mutation in the 3'-flanking region. Clin Investig (1994) 0.96
Concordance between enzyme activity and genotype of glutathione S-transferase theta (GSTT1). Biochem Pharmacol (1998) 0.95
The Biostack experiment on Apollo 16. Life Sci Space Res (1973) 0.95
Variation analysis of six HCV viral load assays using low viremic HCV samples in the range of the clinical decision points for HCV protease inhibitors. Med Microbiol Immunol (2014) 0.95
Genetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadol. Clin Pharmacol Ther (2011) 0.95
Human liver alcohol dehydrogenase. 1. The primary structure of the beta 1 beta 1 isoenzyme. Eur J Biochem (1984) 0.94
Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol (2005) 0.94
Left ventricular volumes by gated equilibrium radionuclide angiography: a new method. Circulation (1979) 0.94
Structure of uncomplexed and linoleate-bound Candida cylindracea cholesterol esterase. Structure (1995) 0.94
Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Res (1996) 0.93
Quantification of the antipsychotics flupentixol and haloperidol in human serum by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl (1998) 0.93
Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction. Cancer Epidemiol Biomarkers Prev (2000) 0.92
Benzydamine N-oxidation as an index reaction reflecting FMO activity in human liver microsomes and impact of FMO3 polymorphisms on enzyme activity. Br J Clin Pharmacol (2000) 0.92
Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. Pharmacogenetics (1999) 0.92
A novel form of the polypeptide PHI isolated in high yield from bovine upper intestine. Relationships to other peptides of the glucagon-secretin family. Eur J Biochem (1984) 0.92
Hanle effect in coherent backscattering. Phys Rev Lett (2002) 0.91
Two severe cases of tick-borne encephalitis despite complete active vaccination--the significance of neutralizing antibodies. J Neurol (2004) 0.91